China Resources Pharmaceutical Group Ltd (3320.HK)
18 Oct 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|60||2016||Non-Executive Chairman of the Board|
|54||2017||Chief Executive Officer, Executive Director|
|45||2016||Chief Financial Officer, Vice President, Executive Director|
|60||2005||President of CR Double-Crane|
|59||2011||President of Dong-E-E-Jiao|
- Chinese biotech firm Ascletis set to open higher in HK debut
- HK's CR Pharma mulls $667 million general offer for Jiangzhong Pharma
- HK's CR Pharma mulls $667 mln general offer for Jiangzhong Pharma
- Deals of the day-Mergers and acquisitions
- China Resources Pharma in talks to buy controlling stake in Jiangzhong